 MediWound Ltd NASDAQ: MDWD has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement removal of dead or infected skin tissue for wound healing of venous leg ulcers VLUs. The study randomized 120 patients, of which 119 patients were treated by either EscharEx n46, a gel vehicle n43, or a non-surgical standard-of-care consisting of either enzymatic or autolytic debridement n30. 